newsfilter
← Latest News
Business Wire·

Blade Therapeutics Announces Positive Topline Data from Phase 1 Clinical Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for Idiopathic Pulmonary Fibrosis

Phase 1 study assessed the effect of cudetaxestat on the pharmacokinetics of a combination of probe substrates for CYP450 enzymes Company on track to initiate planned phase 2 clinical study of cudetaxestat in idiopathic pulmonary fibrosis (IPF) in